Product news
Eli Lilly announced that the FDA has approved Strattera (atomoxetine HCI) for maintenance treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.
Eli Lilly announced that the FDA has approved Strattera (atomoxetine HCI) for maintenance treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.
Get the most out of
Register for free and enjoy unlimited access to: